Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of dolutegravir 50 mg tablets in healthy Thai volunteers
TCTR20220907001Phase 1Terminated
- Sponsor
- Unison Laboratories
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir (2 arms), sponsored by Unison Laboratories. Primary endpoints: Cmax, AUC0-t and 2 more. Started Jun 2024; status: terminated.
02
Drugs
dolutegravir
Beyond the preview
Go deeper on TCTR20220907001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220907001.